drugset / Trial / NCT00398424

Evaluating Patients With Impaired Hepatic Function

NCT00398424

Phase 1 Completed 24 enrolled Taiho Oncology, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase I, Open-Label study evaluating the PK of S-1 components and their metabolites in patients with advanced solid tumors and varying degrees of hepatic function defined by the NCI classification for hepatic impairment. Patients will be stratified into 4 Cohorts- Normal, Mild, Moderate or Severe. Six patients will be enrolled inot each cohort and receive S-1.

Timeline

Start
2006-02
Primary completion
2008-11
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject S-1 Small molecule 30 mg/m2 Oral
Background Cisplatin Other / unclassified

Indications

No indication recorded.